Company Overview of Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of diabetic eye disease and inflammatory bowel disease. It offers tie-2 activators and HIF-1 stabilizers. The company was incorporated in 2011 and is based in Cincinnati, Ohio.
9987 Carver Road
Cincinnati, OH 45242
Founded in 2011
Key Executives for Aerpio Therapeutics, Inc.
Chief Executive Officer and Director
Chief Financial Officer and Vice President
Compensation as of Fiscal Year 2013.
Aerpio Therapeutics, Inc. Key Developments
Aerpio Therapeutics Announces Successful Completion of Phase 1b/2a Trial in Diabetic Macular Edema
Nov 6 13
Aerpio Therapeutics, Inc. announced the successful completion of its Phase 1b/2a study of AKB-9778 for the treatment of diabetic macular edema (DME). Proceeds will support ongoing development of AKB-9778, including an expanded clinical program with a Phase 2 study to confirm monotherapy efficacy and explore adjunctive efficacy with a VEGF inhibitor in DME patients. AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTP) that works to activate Tie2, a receptor on vascular endothelial cells that stabilizes blood vessels, preventing abnormal blood vessel growth and vascular leak. The 28-day Phase 1b/2a ascending dose study of AKB-9778 evaluated the safety and efficacy of AKB-9778 in 24 patients with DME. AKB-9778 was well tolerated throughout 28 days of dosing and produced meaningful changes in retinal thickness and vision gain in some of the treated patients.
Aerpio Therapeutics, Inc. Initiates Phase 1b/2a Trial of AKB-9778 in Diabetic Macular Edema
Sep 19 12
Aerpio Therapeutics, Inc. announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class human protein tyrosine phosphatase beta (HPTP) inhibitor that works to activate Tie2, a receptor on vascular endothelial cells which promotes vascular stability, preventing abnormal blood vessel growth and vascular leak. The 28-day Phase 1b/2a ascending dose study is designed to evaluate the safety and efficacy of AKB-9778 in patients with DME. The study will enroll up to 24 patients at 6 sites throughout the U.S. The primary endpoint is safety with secondary efficacy endpoints based on decreased retinal thickness measured by OCT (optical coherence tomography), improved visual acuity and selected biomarkers. Tie2 is a receptor tyrosine kinase expressed on vascular endothelial cells, which plays a key role in stabilizing blood vessels. AKB--9778 is a first-in-class small molecule that works by inhibiting the Human Protein Tyrosine Phosphatase (HPTP, also known as VE-PTP, or vascular endothelial protein tyrosine phosphatase) enzyme, a negative regulator of the Tie2 receptor. By inhibiting this negative regulator, AKB-9778 restores Tie2 signaling, reducing vascular leak and pathologic neovascularization. Tie2 activators have potential utility in a range of important clinical indications, but Aerpio is currently focusing development of AKB--9778 in diabetic macular edema. In a Phase 1 healthy volunteer study, AKB-9778 was well tolerated through the predicted efficacious dose range, with evidence of on-target pharmacology. Data from a Phase 1b/2a study to explore the safety and efficacy of AKB-9778 in patients with diabetic macular edema is expected in 2013.
Aerpio Appoints Dr. Adrienne Graves to Board of Directors
May 10 12
Aerpio Therapeutics, Inc. announced the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves previously served as President and Chief Executive Officer and Vice President of Worldwide Clinical Development of Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co. Ltd., where she served as a Corporate Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|